Jason Coloma Sells 25,582 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 25,582 shares of Maze Therapeutics stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $26.02, for a total value of $665,643.64. Following the transaction, the chief executive officer directly owned 350,987 shares in the company, valued at $9,132,681.74. The trade was a 6.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Trading Down 1.1%

MAZE traded down $0.30 during midday trading on Wednesday, hitting $26.05. 401,776 shares of the company were exchanged, compared to its average volume of 709,447. The firm has a market capitalization of $1.44 billion, a P/E ratio of -10.30 and a beta of 2.50. Maze Therapeutics, Inc. has a 1-year low of $9.73 and a 1-year high of $53.65. The firm’s 50 day moving average price is $30.19 and its 200-day moving average price is $37.63. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The business had revenue of $20.00 million during the quarter. As a group, equities analysts forecast that Maze Therapeutics, Inc. will post -2.74 EPS for the current fiscal year.

Institutional Trading of Maze Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Washington University increased its position in Maze Therapeutics by 33.3% in the 4th quarter. Washington University now owns 280,802 shares of the company’s stock valued at $11,634,000 after buying an additional 70,121 shares in the last quarter. Mass General Brigham Inc bought a new stake in Maze Therapeutics in the 4th quarter valued at about $9,943,000. ArrowMark Colorado Holdings LLC bought a new stake in Maze Therapeutics in the 3rd quarter valued at about $14,135,000. Boothbay Fund Management LLC increased its position in Maze Therapeutics by 365.9% in the 3rd quarter. Boothbay Fund Management LLC now owns 351,875 shares of the company’s stock valued at $9,124,000 after buying an additional 276,345 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Maze Therapeutics by 27.1% in the 4th quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock valued at $70,307,000 after buying an additional 362,060 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on MAZE. JPMorgan Chase & Co. boosted their price objective on Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, March 31st. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. HC Wainwright boosted their price objective on Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. Wedbush boosted their price objective on Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research note on Monday, March 16th. Finally, BTIG Research reissued a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, March 25th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Maze Therapeutics presently has a consensus rating of “Buy” and an average target price of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.